Joint (JYNT) stock price is $7.37, up 2.79% on the day, as of Oct 22, 2026. It has a market cap of $104.65Mn and a P/E ratio of 27.64, and is classified in the Healthcare Services industry (Healthcare sector).
Enterprise Value
Margins
P/FCF
Key Stats
Market Cap104.65 Mn
P/E27.64
P/S1.79
Revenue Growth (1y) (Qtr)14.41
Add ratio to table…
About
JOINT Corp is a franchisor and operator of chiropractic clinics that follows a private pay cash based model. The company focuses on delivering routine adjustments in an appointment free setting. It aims to be the leading provider of chiropractic care in the markets it serves and to become the most recognized brand in the industry. As of December 31 2025 the company had 960 clinics in operation across 43 states with franchisees owning or managing 885 locations and the company…
JOINT Corp is a franchisor and operator of chiropractic clinics that follows a private pay cash based model. The company focuses on delivering routine adjustments in an appointment free setting. It aims to be the leading provider of chiropractic care in the markets it serves and to become the most recognized brand in the industry. As of December 31 2025 the company had 960 clinics in operation across 43 states with franchisees owning or managing 885 locations and the company owning or managing the remaining 75 clinics. JOINT Corp continues to shift toward a pure play franchisor structure by selling its company owned clinics. The business was founded after acquiring the predecessor to the company in March 2010 and has grown from eight clinics to nearly one thousand locations. Its mission statement emphasizes improving quality of life through routine and affordable chiropractic care. The company’s strategy centers on making care readily available in a retail environment that welcomes walk in patients.
JOINT Corp generates revenue primarily from royalties collected from franchised clinics. The company receives a 7.0 percent royalty on gross sales from each franchise location. In addition it collects a 2.0 percent national marketing fee on the same gross sales. Franchisees also pay an initial franchise fee of $39,900 for each new license sold directly by the company. JOINT Corp shares part of this fee with regional developers who help open clinics in protected territories. The company also earns revenue from the sale of its company owned clinics as part of its refranchising strategy. Beyond core franchising income JOINT Corp receives fees for training programs and support services provided to franchisees. These ancillary contributions help offset corporate overhead and support continued network expansion. The company’s financial reporting treats income from company owned clinics that have been sold as discontinued operations. Overall the diversified revenue base allows JOINT Corp to fund growth initiatives while maintaining a focus on franchising.
JOINT Corp holds the position of the largest chiropractic franchisor in the United States with over 960 clinics operating across 43 states. The company’s scale is approximately six times larger than the next largest chiropractic chain as of December 2025. According to industry research no single company controls more than five percent of the total chiropractic market which remains highly fragmented. JOINT Corp competes against thousands of independent chiropractic offices and several multi unit operators that rely on insurance based reimbursement. The company’s competitive advantages include its appointment free model extended hours of operation and a price point that is roughly fifty percent lower than the average industry charge for similar adjustments. These strengths allow JOINT Corp to attract price sensitive consumers and to build a strong brand presence in retail locations. In addition JOINT Corp benefits from a streamlined operational structure that eliminates the administrative burden of insurance claims processing. This efficiency enables chiropractors to devote more time to patient care and to see a higher volume of visitors each day. The brand’s visibility is reinforced by consistent signage and marketing efforts placed in high traffic shopping centers. Together these factors support JOINT Corp’s leadership position in a competitive and growing wellness sector.
JOINT Corp serves individuals who seek convenient and affordable chiropractic care without the need for appointments. Its typical patient includes adults looking for relief from back neck or joint discomfort as well as those interested in ongoing wellness maintenance. The company attracts a significant share of millennials who value low cost and flexible access to health services. Patients often pay using cash or major credit cards and do not rely on insurance reimbursement for the visits. By focusing on a cash based model JOINT Corp is able to keep prices below typical insurance co payment levels and to appeal to cost conscious consumers. In 2025 the company recorded over 14.4 million patient visits across its network. A substantial portion of those visits came from returning patients who benefited from membership and package plans that encourage regular utilization. Survey data shows that more than one third of new patients had never tried chiropractic care before visiting a JOINT clinic. This indicates that the brand is successful in expanding the overall market for chiropractic services. The company’s locations are chosen for visibility and accessibility in retail settings which further supports its ability to draw walk in traffic.
Sector:HealthcareSector rationaleThe company operates and franchises chiropractic clinics, providing medical services (routine adjustments) to patients. Its primary revenue comes from royalties and fees derived from the delivery of healthcare services, placing it squarely in the Healthcare sector under Healthcare Services.Industry:Healthcare ServicesHealthcare ServicesPrimaryJOINT Corp operates and franchises chiropractic clinics that deliver outpatient care in a retail environment. The company generates revenue from its own clinics and through royalties from franchisees who provide routine adjustments to patients.Classified using BQ-MICSCIK: 0001612630
Bull & bear
Investment Thesis
▲ Bull case
The company's transition to a pure-play franchisor model is substantially complete, with only three company-owned clinics remaining post-transaction, which will drive significant operating leverage as revenue shifts to higher-margin royalty and fee-based streams. This structural change eliminates the drag of company-owned operations on profitability, allowing G&A expenses to decline as a percentage of revenue from current levels toward the targeted 40%-42% range, while gross margins are expected to stabilize at 83%-85% of revenues. The completed refranchising of 132 clinics reduces fixed cost burdens and enables scalable growth without proportional increases in overhead, positioning the business to benefit disproportionately from same-store sales recovery and new franchise openings. Management's confidence in achieving 19%-21% adjusted EBITDA margins once the model is fully realized in the second half of 2026 reflects not just cost savings but a fundamental improvement in the quality of earnings, as the revenue base becomes more predictable and less capital-intensive. This transformation is already yielding results, as evidenced by the 22% year-over-year growth in consolidated adjusted EBITDA to $3.5 million in Q1 despite a 4.9% decline in system-wide sales, demonstrating the immediate impact of operational simplification.
Underpenetrated growth opportunities exist in both geographic expansion and new revenue streams, with management identifying over 1,800 potential U.S. franchise locations and initiating the Joint 3.0 strategy for 2027 focused on B2B partnerships, underserved markets, and international expansion. The first B2B partnership program has already been signed, granting access to employees of partner companies, while the nationwide rollout of the CareCredit financing program opens the door to 12 million potential patients who previously faced payment barriers, directly addressing affordability concerns that may have suppressed demand. These initiatives represent untapped demand channels that are not yet reflected in current same-store sales trends but could drive meaningful acceleration in member acquisition and lifetime value as they scale. The success of early B2B pilots and the absence of patient pushback on CareCredit offerings suggest these programs can be replicated broadly without cannibalizing core business, creating a durable avenue for growth beyond traditional consumer marketing efforts.
Pricing optimization and digital marketing initiatives are creating a self-reinforcing cycle of improved unit economics, with price increases of $5-$10 now implemented in approximately 300 clinics showing no meaningful patient resistance, improved conversion rates, and better retention—particularly through the AlignOne plan that reduces attrition while maintaining visit frequency. The company's AI visibility score has risen to 78-80 from 70, exceeding industry benchmarks and driving higher-quality organic traffic, while fully optimized local microsites are enhancing lead generation and intent signals. These improvements are compounding over time, as evidenced by four consecutive months of month-over-month growth in active member count per clinic, and are expected to accelerate as pricing rolls out enterprise-wide in Q3 and SEO gains continue to build. The ability to increase prices without sacrificing volume indicates strong brand loyalty and pricing power, which, combined with lower customer acquisition costs from digital efficiency, will improve marketing ROI and support sustainable same-store sales growth that could exceed current guidance ranges.
Capital allocation is being used strategically to enhance long-term value, with the company repurchasing 137,000 shares at $8.35 during Q1—below the current trading range—while maintaining $4.5 million remaining under its $12 million authorization and keeping its $20 million credit facility undrawn. Simultaneously, the buyback of three regional developer territories is reducing annual royalty payments by approximately $450,000, increasing the company's retained royalty stream in those markets and improving the quality of future earnings. This dual approach of returning capital to shareholders while selectively acquiring strategic assets demonstrates disciplined capital management that prioritizes per-share value without compromising growth flexibility. The extension of the credit facility to August 2029 provides financial flexibility for future opportunities, and the absence of debt drawdowns reflects confidence in internal cash generation, which is being bolstered by improved free cash flow—up $2.3 million year-over-year—supporting both shareholder returns and reinvestment in growth initiatives like B2B and market expansion.
Management's outlook for same-store sales improvement is grounded in leading indicators that suggest a more robust recovery than current guidance implies, with comp sales already showing sequential improvement from -4.2% in Q1 to approximately -3% year-to-date in April, and the expectation of a clear inflection point in the second half of 2026 as pricing optimization, marketing maturation, and operational efficiencies converge. The company anticipates a pattern of slightly negative comps in Q2 followed by positive comps in Q3 and Q4, with Q4 outperforming Q3, which implies a stronger second-half recovery than the flat to slightly positive full-year guidance range of -3% to +3% might suggest. This trajectory is supported by tangible improvements in patient retention (via extended minimum contracts and the AlignOne plan), higher-intent lead generation from SEO and AI visibility gains, and the rollout of proven pricing strategies—all of which are already showing positive results in the 300 clinics where they have been implemented. The convergence of these factors in the back half of the year creates a credible path to exceeding current comp sales expectations, particularly if new franchise openings continue to outperform historical benchmarks as seen with the 2025 cohort.
The company's transition to a pure-play franchisor model is substantially complete, with only three company-owned clinics remaining post-transaction, which will drive significant operating leverage as revenue shifts to higher-margin royalty and fee-based streams. This structural change eliminates the drag of company-owned operations on profitability, allowing G&A expenses to decline as a percentage of revenue from current levels toward the targeted 40%-42% range, while gross margins are expected to stabilize at 83%-85% of revenues. The completed refranchising of 132 clinics reduces fixed cost burdens and enables scalable growth without proportional increases in overhead, positioning the business to benefit disproportionately from same-store sales recovery and new franchise openings. Management's confidence in achieving 19%-21% adjusted EBITDA margins once the model is fully realized in the second half of 2026 reflects not just cost savings but a fundamental improvement in the quality of earnings, as the revenue base becomes more predictable and less capital-intensive. This transformation is already yielding results, as evidenced by the 22% year-over-year growth in consolidated adjusted EBITDA to $3.5 million in Q1 despite a 4.9% decline in system-wide sales, demonstrating the immediate impact of operational simplification.
Underpenetrated growth opportunities exist in both geographic expansion and new revenue streams, with management identifying over 1,800 potential U.S. franchise locations and initiating the Joint 3.0 strategy for 2027 focused on B2B partnerships, underserved markets, and international expansion. The first B2B partnership program has already been signed, granting access to employees of partner companies, while the nationwide rollout of the CareCredit financing program opens the door to 12 million potential patients who previously faced payment barriers, directly addressing affordability concerns that may have suppressed demand. These initiatives represent untapped demand channels that are not yet reflected in current same-store sales trends but could drive meaningful acceleration in member acquisition and lifetime value as they scale. The success of early B2B pilots and the absence of patient pushback on CareCredit offerings suggest these programs can be replicated broadly without cannibalizing core business, creating a durable avenue for growth beyond traditional consumer marketing efforts.
Pricing optimization and digital marketing initiatives are creating a self-reinforcing cycle of improved unit economics, with price increases of $5-$10 now implemented in approximately 300 clinics showing no meaningful patient resistance, improved conversion rates, and better retention—particularly through the AlignOne plan that reduces attrition while maintaining visit frequency. The company's AI visibility score has risen to 78-80 from 70, exceeding industry benchmarks and driving higher-quality organic traffic, while fully optimized local microsites are enhancing lead generation and intent signals. These improvements are compounding over time, as evidenced by four consecutive months of month-over-month growth in active member count per clinic, and are expected to accelerate as pricing rolls out enterprise-wide in Q3 and SEO gains continue to build. The ability to increase prices without sacrificing volume indicates strong brand loyalty and pricing power, which, combined with lower customer acquisition costs from digital efficiency, will improve marketing ROI and support sustainable same-store sales growth that could exceed current guidance ranges.
Capital allocation is being used strategically to enhance long-term value, with the company repurchasing 137,000 shares at $8.35 during Q1—below the current trading range—while maintaining $4.5 million remaining under its $12 million authorization and keeping its $20 million credit facility undrawn. Simultaneously, the buyback of three regional developer territories is reducing annual royalty payments by approximately $450,000, increasing the company's retained royalty stream in those markets and improving the quality of future earnings. This dual approach of returning capital to shareholders while selectively acquiring strategic assets demonstrates disciplined capital management that prioritizes per-share value without compromising growth flexibility. The extension of the credit facility to August 2029 provides financial flexibility for future opportunities, and the absence of debt drawdowns reflects confidence in internal cash generation, which is being bolstered by improved free cash flow—up $2.3 million year-over-year—supporting both shareholder returns and reinvestment in growth initiatives like B2B and market expansion.
Management's outlook for same-store sales improvement is grounded in leading indicators that suggest a more robust recovery than current guidance implies, with comp sales already showing sequential improvement from -4.2% in Q1 to approximately -3% year-to-date in April, and the expectation of a clear inflection point in the second half of 2026 as pricing optimization, marketing maturation, and operational efficiencies converge. The company anticipates a pattern of slightly negative comps in Q2 followed by positive comps in Q3 and Q4, with Q4 outperforming Q3, which implies a stronger second-half recovery than the flat to slightly positive full-year guidance range of -3% to +3% might suggest. This trajectory is supported by tangible improvements in patient retention (via extended minimum contracts and the AlignOne plan), higher-intent lead generation from SEO and AI visibility gains, and the rollout of proven pricing strategies—all of which are already showing positive results in the 300 clinics where they have been implemented. The convergence of these factors in the back half of the year creates a credible path to exceeding current comp sales expectations, particularly if new franchise openings continue to outperform historical benchmarks as seen with the 2025 cohort.
Despite the successful transition to a near-pure franchisor model, the company continues to face persistent macroeconomic headwinds that are suppressing consumer demand, as evidenced by a 4.9% year-over-year decline in system-wide sales and a -4.2% same-store sales contraction in Q1, with management attributing these trends to general cost-of-living pressures that are unlikely to abate quickly. These challenges are not merely temporary but reflect a structural shift in consumer behavior where discretionary spending on wellness services remains under pressure, and the company's reliance on discretionary income makes it vulnerable to prolonged economic stagnation or further inflationary shocks that could delay or prevent the expected recovery in same-store sales, even as operational improvements take hold. The expectation of sequential improvement in comp sales remains contingent on consumer willingness to spend, which has not yet demonstrated a sustainable rebound, raising the risk that the current traction in member growth and retention may not translate into meaningful sales growth if underlying demand remains weak.
The company's growth trajectory is constrained by the natural maturation of its existing franchise base and the limitations of its current market penetration, with new clinic openings expected to be largely offset by closures as part of ongoing portfolio optimization, resulting in a net stagnant or declining total clinic count through 2026 despite gross openings of 30-35. This dynamic implies that growth must come almost exclusively from same-store sales improvement, which has proven elusive, and places significant pressure on the ability to drive meaningful increases in average unit volume from existing locations—a challenge compounded by the fact that the most promising growth opportunities identified (B2B, underpenetrated geographies, international) are explicitly slated for 2027 and beyond, leaving 2026 heavily dependent on a turnaround in core operations that may not materialize as expected. The reliance on future-oriented initiatives for meaningful expansion creates a near-term growth vacuum where the company must rely on incremental improvements in a challenging environment rather than transformative expansion.
Pricing power may be more limited than management suggests, as the current $5-$10 price increases apply only to new patients, leaving the existing base unaffected and limiting the immediate impact on revenue, while the success of these increases in avoiding patient pushback has not been tested across the full menu of services or in more price-sensitive markets, raising doubts about scalability. The company's acknowledgment that it is leveraging the $10 increase more and that it expects rollout by Q3 implies uncertainty about the optimal price point and the potential for demand elasticity to emerge once the increase reaches a broader audience, particularly if economic pressures intensify. Furthermore, the improvement in retention metrics tied to the AlignOne plan may reflect a shift toward lower-revenue, lower-frequency visits rather than genuine loyalty, potentially undermining the lifetime value gains management anticipates if patients use the plan as a downgrade option rather than a supplement to their existing care.
The financial benefits from regional developer territory buybacks, while accretive to long-term royalty retention, may be overstated due to the offsetting costs of internal management and the limited scale of the savings, with the $450,000 annual reduction in royalties representing a relatively small fraction of the company's projected $12.5-$13.5 million adjusted EBITDA range for 2026, suggesting that these moves, while strategically sound, are not material drivers of near-term profitability. Additionally, the company still has 12 remaining RD territories, and the decision to continue evaluating buybacks implies ongoing capital allocation decisions that could divert resources from growth initiatives or shareholder returns, creating uncertainty about the future trajectory of royalty economics and the potential for further complexity in the franchisor-franchisee relationship if buybacks proceed unevenly across regions.
Near-term profitability and cash flow metrics, while improved year-over-year, remain sensitive to the pace of the refranchising transition and the realization of expected cost savings, with G&A expenses still at $7.1 million in Q1 and only $300,000 of that attributed to costs that will be eliminated post-transition—meaning the bulk of the current G&A base is expected to persist even after the shift to a pure franchisor model, calling into question the speed and magnitude of the anticipated operating leverage. The company's expectation that G&A will decline as a percentage of revenue relies on both numerator (cost) and denominator (revenue) improvements, but if system-wide sales continue to decline or stagnate, the percentage may not fall as projected, undermining the margin expansion thesis. Furthermore, the add-back of most of the $600,000 restructuring charge for adjusted EBITDA suggests that underlying operational costs may be higher than the adjusted metrics imply, and the reliance on non-GAAP adjustments to present profitability could mask persistent inefficiencies that become more apparent as the company scales its franchisor model.
Despite the successful transition to a near-pure franchisor model, the company continues to face persistent macroeconomic headwinds that are suppressing consumer demand, as evidenced by a 4.9% year-over-year decline in system-wide sales and a -4.2% same-store sales contraction in Q1, with management attributing these trends to general cost-of-living pressures that are unlikely to abate quickly. These challenges are not merely temporary but reflect a structural shift in consumer behavior where discretionary spending on wellness services remains under pressure, and the company's reliance on discretionary income makes it vulnerable to prolonged economic stagnation or further inflationary shocks that could delay or prevent the expected recovery in same-store sales, even as operational improvements take hold. The expectation of sequential improvement in comp sales remains contingent on consumer willingness to spend, which has not yet demonstrated a sustainable rebound, raising the risk that the current traction in member growth and retention may not translate into meaningful sales growth if underlying demand remains weak.
The company's growth trajectory is constrained by the natural maturation of its existing franchise base and the limitations of its current market penetration, with new clinic openings expected to be largely offset by closures as part of ongoing portfolio optimization, resulting in a net stagnant or declining total clinic count through 2026 despite gross openings of 30-35. This dynamic implies that growth must come almost exclusively from same-store sales improvement, which has proven elusive, and places significant pressure on the ability to drive meaningful increases in average unit volume from existing locations—a challenge compounded by the fact that the most promising growth opportunities identified (B2B, underpenetrated geographies, international) are explicitly slated for 2027 and beyond, leaving 2026 heavily dependent on a turnaround in core operations that may not materialize as expected. The reliance on future-oriented initiatives for meaningful expansion creates a near-term growth vacuum where the company must rely on incremental improvements in a challenging environment rather than transformative expansion.
Pricing power may be more limited than management suggests, as the current $5-$10 price increases apply only to new patients, leaving the existing base unaffected and limiting the immediate impact on revenue, while the success of these increases in avoiding patient pushback has not been tested across the full menu of services or in more price-sensitive markets, raising doubts about scalability. The company's acknowledgment that it is leveraging the $10 increase more and that it expects rollout by Q3 implies uncertainty about the optimal price point and the potential for demand elasticity to emerge once the increase reaches a broader audience, particularly if economic pressures intensify. Furthermore, the improvement in retention metrics tied to the AlignOne plan may reflect a shift toward lower-revenue, lower-frequency visits rather than genuine loyalty, potentially undermining the lifetime value gains management anticipates if patients use the plan as a downgrade option rather than a supplement to their existing care.
The financial benefits from regional developer territory buybacks, while accretive to long-term royalty retention, may be overstated due to the offsetting costs of internal management and the limited scale of the savings, with the $450,000 annual reduction in royalties representing a relatively small fraction of the company's projected $12.5-$13.5 million adjusted EBITDA range for 2026, suggesting that these moves, while strategically sound, are not material drivers of near-term profitability. Additionally, the company still has 12 remaining RD territories, and the decision to continue evaluating buybacks implies ongoing capital allocation decisions that could divert resources from growth initiatives or shareholder returns, creating uncertainty about the future trajectory of royalty economics and the potential for further complexity in the franchisor-franchisee relationship if buybacks proceed unevenly across regions.
Near-term profitability and cash flow metrics, while improved year-over-year, remain sensitive to the pace of the refranchising transition and the realization of expected cost savings, with G&A expenses still at $7.1 million in Q1 and only $300,000 of that attributed to costs that will be eliminated post-transition—meaning the bulk of the current G&A base is expected to persist even after the shift to a pure franchisor model, calling into question the speed and magnitude of the anticipated operating leverage. The company's expectation that G&A will decline as a percentage of revenue relies on both numerator (cost) and denominator (revenue) improvements, but if system-wide sales continue to decline or stagnate, the percentage may not fall as projected, undermining the margin expansion thesis. Furthermore, the add-back of most of the $600,000 restructuring charge for adjusted EBITDA suggests that underlying operational costs may be higher than the adjusted metrics imply, and the reliance on non-GAAP adjustments to present profitability could mask persistent inefficiencies that become more apparent as the company scales its franchisor model.